Search

everythinglearnresearchcommunity

for

Search:↓

PRIDE syndrome includes skin and hair issues from cancer treatment with EGFR inhibitors.

Keratin 16 delays skin maturation and affects skin and hair development in mice.

Skin side effects from cancer drugs targeting EGFR can affect treatment adherence but can be managed with antibiotics like tetracycline.

Inactivating both p53 and Rb genes in mice speeds up aggressive skin cancer development.

EGFR-TKIs can cause significant skin, nail, and organ side effects.

Gefitinib can cause hair loss without scarring.

Some medications can cause hair loss, but stopping the drug usually leads to recovery within 3 months.

Blocking certain proteins can reduce skin inflammation caused by cancer treatment.

EGFR inhibitors can cause skin issues like acne and dryness, but these can be managed without stopping treatment.

Combining irinotecan and cetuximab is effective for some metastatic colorectal cancer patients but often causes manageable skin issues.

Understanding EGFR roles could lead to new hair loss treatments.

A cancer patient died from a severe skin reaction after taking the drug cetuximab.

Overexpressing the epigen gene in mice leads to enlarged sebaceous glands and greasy fur.

Erlotinib can cause nonscarring hair loss and itchy skin.

Erlotinib may cause scarring hair loss.

Reduced EGFR signaling delays hair cycle and reduces fat growth, but hair development remains normal.

Blocking IL-8 can reduce skin rashes from cancer treatment.

Cetuximab can cause eyelash growth, which is rare but manageable.

Allopregnanolone increases growth and changes gene activity in human brain cancer cells.

Erlotinib can cause hair loss as a side effect.

Genetic changes in mice help understand skin and hair disorders, aiding treatment development for acne and hair loss.

EGFR hyperactivation increases sebaceous gland size and sebum production in mice.

The guidelines help doctors manage skin problems from certain cancer treatments to improve patients' lives.

Reducing gefitinib dosage improved hair loss, but scarring remained.

CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.

Targeting EGFR may help reduce hair loss from chemotherapy.

Topical human epidermal growth factor may effectively treat acne caused by cancer medication.

EGFR inhibitors can cause yellowish skin eruptions.

Targeted cancer therapies can cause skin side effects, which should be treated early to help patients' quality of life and treatment adherence.

Activating Nrf2 in skin cells speeds up wound healing by increasing the growth of certain stem cells.